Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4975284 | 1.00 | CA2 (0.32) | CA2MEN1KMT2ACA1 | |
| SCHEMBL11491429 | 1.00 | CA2 (0.32) | CA2MEN1KMT2ACA1 | |
| SCHEMBL968053 | 1.00 | CA2 (0.32) | CA2MEN1KMT2ACA1 | |
| SCHEMBL968055 | 1.00 | CA2 (0.32) | CA2MEN1KMT2ACA1 | |
| SCHEMBL4975291 | 1.00 | CA2 (0.32) | CA2MEN1KMT2ACA1 | |
| SCHEMBL8838682 | 1.00 | CA2 (0.32) | CA2MEN1KMT2ACA1 | |
| SCHEMBL4975685 | 0.98 | MEN1 (0.32) | CA2MEN1KMT2A | |
| SCHEMBL11405856 | 0.98 | MEN1 (0.32) | CA2MEN1KMT2A | |
| SCHEMBL4975682 | 0.98 | MEN1 (0.32) | CA2MEN1KMT2A | |
| SCHEMBL11405854 | 0.98 | MEN1 (0.32) | CA2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2864308-B1 | (3aR,6aS)-2-Hydroxy-3,3a,6,6a-tetrahydro-2H-cyclopenta[b]furan-5-carbaldehyde intermediates for the preparation of prostaglandins or prostaglandin analogues | UNIV BRISTOL (GB) | 2016-10-19 | — | — | EP | disclosed |
| US-9242954-B2 | Lactol and acetal intermediates for making prostaglandins | UNIVERSITY OF BRISTOL (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20150158837-A1 | Compound And Method | TOPOKINE THERAPEUTICS, INC. | 2015-06-11 | — | — | US | disclosed |
| US-5194670-A | Storage stability | YUTAKA MIZUSHIMA, ASAHI GLASS COMPANY LTD. (JP) | 1993-03-16 | — | — | US | disclosed |
| EP-0423697-A2 | Emulsion of lipid containing a prostaglandin analogue | MIZUSHIMA, Yutaka (JP) | 1991-04-24 | — | — | EP | disclosed |
| US-4845282-A | CHEMICAL INTERMEDIATES | TEIJIN LIMITED (JP) | 1989-07-04 | — | — | US | disclosed |
| US-4766147-A | ANTITUMOR AGENTS | TEIJIN LIMITED (JP) | 1988-08-23 | — | — | US | disclosed |
| EP-0106576-B1 | NOVEL 5-MEMBERED CYCLIC COMPOUNDS, PROCESS FOR THE PRODUCTION THEREOF, AND PHARMACEUTICAL USE THEREOF | TEIJIN LIMITED (JP) | 1988-03-09 | — | — | EP | disclosed |
| EP-0079733-B1 | PROCESS FOR PROSTAGLANDIN E1, PRODUCTION AND NOVEL DELTA 7-PROSTAGLANDINES E AND 7-HYDROXYPROSTAGLANDINS E | TEIJIN LIMITED (JP) | 1987-03-04 | — | — | EP | disclosed |
| US-4578482-A | Process for preparing prostacyclins | TEIJIN LIMITED (JP) | 1986-03-25 | — | — | US | disclosed |
| EP-0100900-B1 | NOVEL (3.2.0.) BICYCLOHEPTANONE OXIME ETHERS WITH VALUABLE THERAPEUTIC PROPERTIES | SYNTEX (U.S.A.) INC. (US) | 1986-02-05 | — | — | EP | disclosed |
| US-4552898-A | CARDIOVASCULAR DISORDERS | SYNTEX (U.S.A.) INC. (US) | 1985-11-12 | — | — | US | disclosed |
| EP-0112633-A2 | Novel 5-thiaprostaglandin, process for production thereof, and pharmaceutical use thereof | TEIJIN LIMITED (JP) | 1984-07-04 | — | — | EP | disclosed |
| EP-0106576-A2 | Novel 5-membered cyclic compounds, process for the production thereof, and pharmaceutical use thereof | TEIJIN LIMITED (JP) | 1984-04-25 | — | — | EP | disclosed |
| EP-0100900-A1 | Novel (3.2.0.) bicycloheptanone oxime ethers with valuable therapeutic properties | SYNTEX (U.S.A.) INC. (US) | 1984-02-22 | — | — | EP | disclosed |
| US-4423068-A | (3.2.0) Bicycloheptanone oxime ethers with therapeutic properties | SYNTEX (U.S.A.) INC. (US) | 1983-12-27 | — | — | US | disclosed |
| US-4390721-A | 3-Endo-protected hydroxyl-tricyclo[3,2,0,02,7 ]heptan-6-ones | ALLEN & HANBURYS LIMITED (GB) | 1983-06-28 | — | — | US | disclosed |
| US-4272629-A | Novel prostaglandin intermediates | ALLEN & HANBURYS LIMITED (GB) | 1981-06-09 | — | — | US | disclosed |
| US-4181674-A | 5-Endo-protected hydroxyl-bicyclo[2,2,1]-heptan-2-ones and process for preparing same | ALLEN & HANBURYS LIMITED (GB) | 1980-01-01 | — | — | US | disclosed |
| US-4134911-A | 3-Endo-protected hydroxyl-tricyclo[3,2,0,02,7 ]-heptan-6-ones | ALLEN & HANBURYS LIMITED (GB) | 1979-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158837-A1 | Compound And Method | CYP4A11, NR1H2, NR1H3 | CA2 3363/4885MEN1 2871/4885KMT2A 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.